In this commentary, Michael J. Bloch, MD writes about controversies in the effect of dietary cholesterol and egg consumption on cardiovascular events and mortality.
In this article, James Matera, DO, writes about a newer agent, finarenone, which is a nonsteroidal, selective mineralocorticoid receptor antagonist that can treat chronic kidney disease.
He talks about the prevalence of sudden cardiac arrest among younger athletes, how to risk stratify this population, and the controversy around using electrocardiogram imaging in standard care.
Andres Pineda Maldonado, MD, from the University of Florida, Jacksonville, answers our questions about new therapies for mitral valve disease, the different recommendations for men vs women, and more.
Peter H. Jones, MD, discussed identifying high-risk patients and targeting specific lipid therapy to reduce risk of future cardiovascular disease events.
The Consumer Technology Association and Heart Rhythm Society have released new guidance on the best practices for consumers who use wearable devices. Lead author Nassir F. Marrouche, MD, from Tulane...
Sean L. Zheng, BM, BCh, MA, MRCP, of King’s College Hospital NHS Foundation Trust, discusses key clinical takeaways from his new study, which provided evidence of the benefits and risks of aspirin for...
He discusses his research on the gut-heart axis, the role of the gut-heart axis as a potential new target for atherosclerosis therapies, and potential therapeutic implications.
In this podcast, Jeffrey Tabas, MD, shares his thoughts on the next steps for research on atrial fibrillation, including the types of studies still needed.
He discusses his team's research on metabolomic profiles of coronary heart disease in African Americans and the gender differences in these metabolomic profiles.
